1st Apr 2010 15:30
Annual Information Update
April 1, 2010 - Shire plc , the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2009 and March 31, 2010.
The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.
1. Announcements made via a RIS
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
25-Mar-10 Shire Presents Positive Data for Patients with Type 1 Gaucher Disease who Switched to VPRIVâ„¢ 25-Mar-10 Publication of Shire plc's Annual Report 2009 18-Mar-10 Director/PDMR Shareholding 16-Mar-10 Shire Receives INTUNIV Paragraph IV Notice Letter from Teva Pharmaceuticals 15-Mar-10 New Board Director Appointed 11-Mar-10 Director/PDMR Shareholding 09-Mar-10 Director/PDMR Shareholding 05-Mar-10 Director/PDMR Shareholding 04-Mar-10 District Court Upholds FDA's Grant of 5-Year Market Exclusivity to VYVANSE® 03-Mar-10 Director/PDMR Shareholding 03-Mar-10 Director/PDMR Shareholding 02-Mar-10 Supplementary Reporting Announcement 01-Mar-10 Elections for Interim Dividend in Respect of the Six Months to December 31, 2009 01-Mar-10 Total Voting Rights 01-Mar-10 Shire Announces FDA Approval of VPRIVâ„¢ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 24-Feb-10 Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA) 19-Feb-10 Excellent results in a transformational year for Shire; core product sales up 25% 11-Feb-10 Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Na¯ve Patients with Type 1 Gaucher Disease 04-Feb-10 Full Year 2009 results date notification - 19 February 2010 01-Feb-10 Total Voting Rights 26-Jan-10 Holding(s) in Company 18-Jan-10 Directorate Change 04-Jan-10 Total Voting Rights 29-Dec-09 Director/PDMR Shareholding 23-Dec-09 Dr Michael Rosenblatt to step down as non-executive director 22-Dec-09 Shire Submits Biologics License Application (BLA) for REPLAGAL® with the U.S. Food and Drug Administration (FDA) 16-Dec-09 Membership of Board Committees 16-Dec-09 Director/PDMR Shareholding 14-Dec-09 Director/PDMR Shareholding 11-Dec-09 Director/PDMR Shareholding 07-Dec-09 Holding(s) in Company 02-Dec-09 Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic 01-Dec-09 Total Voting Rights 24-Nov-09 Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 23-Nov-09 Block listing six monthly return 12-Nov-09 PDMR Shareholding 04-Nov-09 FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease 03-Nov-09 Directors/PDMR Shareholding 02-Nov-09 Total Voting Rights 02-Nov-09 New Shire Board member 30-Oct-09 3rd Quarter Results - Shire continues to deliver excellent growth from core products 26-Oct-09 FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity 22-Oct-09 Third quarter 2009 results date notification - October 30, 2009 21-Oct-09 Shire Targets Fourth Quarter Filing of BLA for REPLAGAL® for Fabry Disease with U.S. FDA 15-Oct-09 Holding(s) in Company 01-Oct-09 Total Voting Rights 25-Sep-09 Director/PDMR Shareholding 22-Sep-09 Director/PDMR Shareholding 18-Sep-09 Director/PDMR Shareholding 08-Sep-09 Update on velaglucerase alfa 04-Sep-09 Director/PDMR Shareholding 03-Sep-09 Director/PDMR Shareholding 03-Sep-09 Shire Announces FDA Approval of Once-Daily INTUNIVâ„¢ (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17 01-Sep-09 Total Voting Rights 01-Sep-09 Elections for interim dividend in respect of the six months to June 30, 2009 01-Sep-09 Shire Completes Submission of NDA for velaglucerase alfa for Type 1 Gaucher disease and Reports Positive Results for Remaining Two Phase III Trials 21-Aug-09 Half Yearly Report 19-Aug-09 Director/PDMR Shareholding 07-Aug-09 Membership of Board Committees 05-Aug-09 Q2 results - Core portfolio of products delivers 20% sales growth 03-Aug-09 Total Voting Rights 03-Aug-09 Shire Reports Positive Results from First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions with FDA 28-Jul-09 FDA Issues Complete Response Letter for INTUNIVâ„¢ (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents 21-Jul-09 Second quarter 2009 results date notification - August 5, 2009 16-Jul-09 Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 09-Jul-09 Dr Jeffrey Leiden appointed to Vertex Board. 07-Jul-09 Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease 01-Jul-09 Total Voting Rights 01-Jun-09 Total Voting Rights 26-May-09 Block Listing Six Monthly Return 22-May-09 Director/PDMR Shareholding 12-May-09 Director/PDMR Shareholding 01-May-09 Total Voting Rights 30-Apr-09 Shire begins the year with a strong performance 28-Apr-09 Results of the Annual General Meeting held on April 28, 2009 20-Apr-09 First quarter 2009 results date notification - April 30, 2009 02-Apr-09 Shire files lawsuit against Natco Pharma for infringement of FOSRENOL® (lanthanum carbonate) patents 01-Apr-09 Director/PDMR Shareholding 01-Apr-09 Holding(s) in Company 01-Apr-09 Total Voting Rights 01-Apr-09 Annual Information Update
2. Documents filed with the Securities and Exchange Commission ("SEC")
The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC's website at www.sec.gov.
3. Documents filed with Companies Registry, Jersey
Date of Delivery Document
24-Feb-10 Annual Return
01-May-09 Special Resolution passed on April 28, 2009
22-Apr-09 Annual Report and Accounts for the year ended December 31, 2008
4. Documents sent to Shareholders
The following documents were published and sent to shareholders, and are available on the Company's website.
Date of Delivery Document
25-Mar-10 Annual Report and Accounts for the year ended December 31, 2009
25-Mar-10 Notice of 2010 Annual General Meeting
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company's registered office.
Tony GuthrieDeputy Company Secretary
For further information please contact:
Investor Cl©a Rosenfeld (Rest of the World) +44 1256 894 160 Relations Eric Rojas (North America) +1 781 482 0999 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com
vendorRelated Shares:
Shire